The global pancreatic cancer drugs market is expected to grow from USD 1,619.5 million in 2018 to USD 2,824.7 million by 2028 at a compound annual growth rate (CAGR) of 8.4% during the forecast period from 2018-2028.
Pancreatic cancer drugs are substances that may be used to treat pancreatic cancer. The type of treatment a person receives depends on the stage and type of pancreatic cancer they have, as well as their age and general health. There is no cure for pancreatic cancer, so treatments focus on slowing down its growth until it can be eliminated or cured by surgery.
On the basis of type, the global pancreatic cancer drugs market is segmented into Drugs Approved for Pancreatic Cancer, Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation), Afinitor (Everolimus), Erlotinib Hydrochloride, Everolimus, Fluorouracil Injection, Gemcitabine Hydrochloride.
The drugs approved for pancreatic cancer include Abraxane (Paclitaxel Albumin-Stabilized Nanoparticle Formulation), Afinitor (Everolimus), Erlotinib Hydrochloride, Everolimus, and Gemcitabine Hydrochloride. These come in the form of tablets or injections, depending on the drug.
Abraxane is a type of drug approved for pancreatic cancer treatment. It's also known as Paclitaxel Albumin-stabilized Nanoparticle Formulation, which has some advantages over traditional chemotherapy drugs. Abraxane consists of nanoparticles that are stabilized by albumin to help them attach and stay inside the tumor cells longer than other types of chemotherapy medications. This helps stop metastasis (cancer spreading from one organ or area in the body). Pancreatic Cancer Treatment with Abraxane - How Does it Work? Patients receive an infusion intravenously once per week for up to six weeks followed by another cycle every three months until they can no longer tolerate their side effects because this medication could damage organs like your kidneys if used too long.
Afinitor (Everolimus) is a cancer treatment medication. It works by blocking the action of certain proteins that can cause uncontrolled cell growth in some types of cancer cells. Afinitor and similar medications are called tyrosine kinase inhibitors, or TKIs for short. This type of medicine helps to prevent new blood vessel formation required for tumor growth and kills rapidly dividing abnormal blood cells as well as other fast-growing cancers such as myeloma, leukemia, lymphomas, sarcomas, and plasmacytoma. Afinitor is used to treat various types of cancer, including kidney cancer.
Erlotinib Hydrochloride is used to treat pancreatic cancer. It belongs to a group of medicines called tyrosine kinase inhibitors (TKIs). Erlotinib Hydrochloride blocks the action of certain substances in the body that promote cancer. This slows down the growth of cancer cells.
Erlotinib Hydrochloride is used to treat pancreatic cancer that has not been treated before or spread outside the pancreas (usually advanced stages). It may also be used as a second-line treatment after gemcitabine-based therapy and, in some cases, chemotherapy when tumors cannot be removed by surgery.
Everolimus, also known by its trade name Afinitor®, is a drug in the class of immunosuppressants. The FDA approved it for use as adjuvant therapy to prevent recurrence after surgery (abdominal and pancreatic cancer) or radiotherapy for hepatocellular carcinoma. It binds to an intracellular protein called mTOR that controls cell growth. By binding, Everolimus inhibits the activity of this protein which halts tumor expansion across different organ systems. Furthermore, it can be used in combination with other medications such as Erlotinib Hydrochloride and Gemcitabine Hydrochloride.
Fluorouracil Injection is a chemotherapy drug that interferes with the growth of cancer cells. It belongs to a group of medicines called "antimetabolites." Fluorouracil works by interfering with DNA replication and cell division. When it enters normal body cells, fluorouracil acid leaves them unable to divide or reproduce themselves normally. This may stop cancer from growing so quickly (in some cases). In addition, when used as an antineoplastic agent in specific situations such as treatment for breast tumors that have spread outside the breast before they can be surgically removed, fluoro-uracil medication has been found effective because it slows down tumor progression. Fluorouracil is also used to prevent the spread of tumors in people with cancer that has been removed by surgery.
Gemcitabine hydrochloride is an anti-cancer drug of the gemcitabine family. It was developed by Eli Lilly and Company in 1974 as a chemotherapy agent for human pancreatic cancer and has since been used to treat other cancers. Gemcitabine hydrochloride belongs to the class of drugs called nucleosides which act on DNA synthesis in cells during cell division (mitosis). Like all cytotoxic agents, it also affects normal tissues that are rapidly dividing such as hair follicles and bone marrow.
On the basis of application, the global pancreatic cancer drugs market is segmented into Hospitals, Clinics.
the application in hospitals is focused on the treatment of pancreatic cancer. Hospitals use gemcitabine hydrochloride to kill dividing cells that are responsible for cancerous growths or tumors. This drug, like other anti-cancer drugs, works by interfering with cell division and replication which can be caused due to faulty DNA material being copied from a parent chromosome into new chromosomes (chromosomes). Cancer occurs when there is an uncontrolled and abnormal rate of multiplication of these damaged cells.
Clinics use pancreatic cancer drugs to help patients with the disease. The type of drug varies depending on what stage it is, but chemotherapy like Gemcitabine and Fluorouracil are given as a first-line response for this treatment option. When prescribed intravenously or injected into the abdomen, these medications can be administered in cycles that last from six weeks up to eight months.
On the basis of region, the global pancreatic cancer drugs market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
North America accounted for the largest market share of global pancreatic cancer drugs. In 2017, it was followed by Europe and the Asia Pacific respectively due to the increasing rate of obesity in these regions.
The future estimates indicate that North America will continue to dominate until 2024 because of a growing elderly population and high prevalence rates among people above 50 years old who are at risk from this disease.
Asia-Pacific region is expected to witness significant growth owing to an increased demand for anti-cancer therapies amid rising health awareness across emerging countries such as India, China, South Korea, etc., which majorly contribute towards the total revenue generated through sales of drugs used for treating pancreatic cancer like Afinitor (Everolimus). Oncologists and physicians in the Asia-Pacific region are increasingly adopting modern treatment methods and novel therapies for pancreatic cancer, which is also expected to drive demand over the next ten years.
Middle East country like Saudi Arabia has emerged as a hot spot for pancreatic cancer drugs market owing to its rapidly rising population and increasing adoption of western lifestyle which will significantly contribute towards the growth of this region during the forecast period from 2019-2028.
The growth factors for the global pancreatic drugs market include introduction and approval process approvals for new drugs such as Afinitor (Everolimus), Erlotinib Hydrochloride, Everolimus, and Gemcitabine Hydrochloride in recent years. The growth factors also include the introduction of newer drugs such as Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation).
The global pancreatic cancer market is driven by the number of new cases diagnosed with this disease each year. In 2017, globally there were around 225000 new cases reported. As more people are getting diagnosed with this ailment every year it has led to a spike in demand for treatment options which has further fueled the drug market growth. This high incidence rate is expected to increase from now until 2030 when experts predict that about 290000 new diagnoses will be made annually worldwide.
Up Market Research published a new report titled “Pancreatic Cancer Drugs Market research report which is segmented by Types (Drugs Approved for Pancreatic Cancer, Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation), Afinitor (Everolimus), Erlotinib Hydrochloride, Everolimus, 5-FU (Fluorouracil Injection), Fluorouracil Injection, Gemcitabine Hydrochloride, Other), By Applications (Hospitals, Clinics), By Players/Companies Eli Lilly and Company, Celgene, Roche, Novartis, Clovis Oncology, Amgen, Merck, Teva Pharmaceutical Industries, Pfizer, PharmaCyte Biotech”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.
|Report Attributes||Report Details|
|Report Title||Pancreatic Cancer Drugs Market Research Report|
|By Type||Drugs Approved for Pancreatic Cancer, Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation), Afinitor (Everolimus), Erlotinib Hydrochloride, Everolimus, 5-FU (Fluorouracil Injection), Fluorouracil Injection, Gemcitabine Hydrochloride, Other|
|By Application||Hospitals, Clinics|
|By Companies||Eli Lilly and Company, Celgene, Roche, Novartis, Clovis Oncology, Amgen, Merck, Teva Pharmaceutical Industries, Pfizer, PharmaCyte Biotech|
|Regions Covered||North America, Europe, APAC, Latin America, MEA|
|Historical Year||2018 to 2019 (Data from 2010 can be provided as per availability)|
|Number of Pages||247|
|Number of Tables & Figures||173|
|Customization Available||Yes, the report can be customized as per your need.|
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
The market is segmented by Type Drugs Approved for Pancreatic Cancer, Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation), Afinitor (Everolimus), Erlotinib Hydrochloride, Everolimus, 5-FU (Fluorouracil Injection), Fluorouracil Injection, Gemcitabine Hydrochloride, Other and By Application Hospitals, Clinics.
Some of the companies that are profiled in this report are:
Pancreatic Cancer Drugs Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
We have studied the Pancreatic Cancer Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
Reasons to Purchase the Pancreatic Cancer Drugs Market Report:
Some other reports from this category!